E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016

E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016
Published Aug 10, 2016
73 pages — Published Aug 10, 2016
Price US$ 3,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016, provides in depth analysis on E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted pipeline therapeutics.

The report provides comprehensive information on the E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.)
- The report reviews E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics and enlists all their major and minor projects
- The report assesses E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- Th

  
Source:
Document ID
GMDHC0462TDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents25
  List of Tables61
  List of Figures61
Introduction71
  Global Markets Direct Report Coverage71
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Overview81
Therapeutics Development94
  E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Products under Development by Stage of Development91
  E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Products under Development by Therapy Area101
  E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Products under Development by Indication112
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Pipeline Products Glance132
  Late Stage Products131
  Early Stage Products141
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Products under Development by Companies154
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Products under Development by Universities/Institutes192
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Therapeutics Assessment216
  Assessment by Monotherapy/Combination Products211
  Assessment by Mechanism of Action221
  Assessment by Route of Administration232
  Assessment by Molecule Type252
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Companies Involved in Therapeutics Development277
  Aileron Therapeutics, Inc.271
  Amgen Inc.281
  Ascentage Pharma Group Corporation, Ltd.291
  Daiichi Sankyo Company, Limited301
  F. Hoffmann-La Roche Ltd.311
  Merck &Co., Inc.321
  Novartis AG331
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Drug Profiles3430
  ALRN-6924 Drug Profile342
  AM-7209 Drug Profile361
  AMG-232 Drug Profile371
  APG-115 Drug Profile381
  ATSP-7041 Drug Profile392
  CGM-097 Drug Profile411
  DS-3032 Drug Profile421
  DS-5272 Drug Profile431
  HDM-201 Drug Profile441
  idasanutlin Drug Profile452
  ISA-27 Drug Profile471
  MI-888 Drug Profile481
  MK-8242 Drug Profile491
  MMRi-64 Drug Profile501
  nutlin-3 Drug Profile511
  R-xxx Drug Profile521
  RG-7775 Drug Profile531
  RO-8994 Drug Profile541
  Small Molecule 1 to Inhibit MDM2 for Oncology Drug Profile551
  Small Molecule 2 to Inhibit MDM2 for Oncology Drug Profile561
  Small Molecule 3 to Inhibit MDM2 for Oncology Drug Profile571
  Small Molecules to Inhibit MDM2 and MDM4 for Acute Lymphoblastic Leukemia Drug Profile581
  Small Molecules to Inhibit MDM2 for Breast Cancer Drug Profile591
  Small Molecules to Inhibit p53-hdm2 for Oncology Drug Profile601
  Small Molecules to Inhibit p53-MDM2 Interaction for Cancer Drug Profile611
  Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy Drug Profile621
  Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer Drug Profile631
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Dormant Projects643
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Discontinued Products671
E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Featured News &Press Releases684
  Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53681
  Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH691
  Aug 15, 2013: Aileron Therapeutics Publishes Data Demonstrating ATSP-7041 as First-in-class p53 Pathway Re-activator for the Treatment of Solid and Hematologic Cancers691
  Nov 07, 2012: Aileron Therapeutics Presents New Data On Stapled Peptide Oncology Program At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics701
  Oct 31, 2012: Aileron Therapeutics To Present Data On Stapled Peptides At Upcoming Scientific Conferences And Industry Events711
Appendix722
  Methodology721
  Coverage721
  Secondary Research721
  Primary Research721
  Expert Panel Validation721
  Contact Us721
  Disclaimer731

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/E3-Ubiquitin-Protein-Ligase-Mdm2-Double-Minute-2-Protein-or-Hdm2-or-Oncoprotein-Mdm2-or-p53-Binding-Protein-Mdm2-or-MDM2-or-EC-6-3-2-Pipeline-Review-H2-2016-2088-16382>
  
APA:
Global Markets Direct - Market Research. (2016). E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/E3-Ubiquitin-Protein-Ligase-Mdm2-Double-Minute-2-Protein-or-Hdm2-or-Oncoprotein-Mdm2-or-p53-Binding-Protein-Mdm2-or-MDM2-or-EC-6-3-2-Pipeline-Review-H2-2016-2088-16382>
  
US$ 3,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.